About Kohjin Bio
Kohjin Bio is a publicly listed company based in Sakado (Japan) founded in 1981. It operates as a tissue culture media provided for regenerative medicine and immunotherapy research. The company has 167 employees. Its chief executive is Takato Nakamura. Its website kohjin-bio.jp draws about 11 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Cell Culture. Its competitors include Multus, Metatissue, Nu-Tek Biosciences, Sarvoshadhi Bio and metabolIQ and 3 more; 3 of its 8 listed competitors have raised funding.
Company details
Kohjin Bio was founded in 1981 in Sakado, Japan, as a provider of tissue culture media. Focus is placed on developing serum-free media for research applications in regenerative medicine and immunotherapy. Operations center on the production and supply of these specialized media to support scientific investigations in the biotechnology sector. The companys activities are based in Japan, serving global research needs.
- Headquarters Sakado, Japan
- Employees 167
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website kohjin-bio.jp
- Legal Name Kohjin Bio Co.,Ltd.
- Annual Revenue$30.97 M (USD)-5.13as on Mar 31, 2026
- Net Profit$1.57 M (USD)-68.42as on Mar 31, 2026
- EBITDA$4.63 M (USD)-45.44as on Mar 31, 2026
- Employee Count167
People of Kohjin Bio
1 people are tracked at Kohjin Bio (1 in leadership); the tracked headcount is 167.
| Name | Role | Group |
|---|---|---|
Takato Nakamura | CEO | Leadership |
Complete people profiles for Kohjin Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kohjin Bio
Kohjin Bio is a publicly listed company on the TSE with ticker symbol 177A in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Apr 2024
- Listed onTSE: 177A
- Listed entityKohjin Bio Co.,Ltd.
- Exchange sectorHealth technology
- ISINJP3283630006
- Share price816.00 JPY (+0.49% on the day) · 2026-10-14
- Market capitalisation4,150,619,137.00 JPY
- Price to earnings32.9
- EPS (diluted, trailing year)24.81 JPY
- Dividend yield1.23%
- Volume (last session)900
Financials of Kohjin Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.94B JPY | 251.0M JPY | 737.7M JPY |
| 2024 | 5.21B JPY | 794.8M JPY | 1.35B JPY |
| 2023 | 4.77B JPY | 385.0M JPY | 896.5M JPY |
| 2022 | 4.74B JPY | 829.8M JPY | 1.44B JPY |
| 2021 | 3.95B JPY | 587.7M JPY | 1.15B JPY |
Detailed financial statements for Kohjin Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Kohjin Bio
Kohjin Bio has 8 listed competitors in our database, 3 of them funded. They include Multus, Metatissue, Nu-Tek Biosciences, Sarvoshadhi Bio and metabolIQ, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| multus.bio | 2019 | London, United Kingdom | $9.3M | 8 | Provider of lab-grown meat alternatives | |
| metatissue.com | 2018 | Ilhavo, Portugal | – | – | Provider of human protein-based products for cell culture, tissue engineering, and disease modeling applications | |
| nu-tekbiosciences.com | 2008 | Minnetonka, United States | – | – | Develops innovative animal-free peptones and cell culture media for pharmaceutical use. | |
| sarvoshadhi.com | 2017 | Kolhapur, India | – | – | Customized cell culture media for biotechnology are developed. | |
| metaboliq.ca | 2022 | Canada | – | – | Developer of cell culture medium for pharmaceutical screening and personalized medicine | |
| onkologic.com | 2021 | Farmington, United States | $305,000 | – | NK cell culture media is developed for cancer cell therapies. | |
| alt-biotech.com | 2023 | Evry Courcouronnes, France | – | – | Delivers comprehensive cell-culture solutions for producing non-therapeutic recombinant proteins. | |
| cet.bio | 2000 | Coralville, United States | $45,000 | – | Cell lines and stem cell products are supplied to researchers. |
Detailed competitors of Kohjin Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kohjin Bio
The website of Kohjin Bio (kohjin-bio.jp) receives about 11K visits a month and ranks #2,602,557 among all websites worldwide, #3,566 in Biotechnology and Pharmaceuticals.
- Monthly visits11K
▲ 94.3% vs previous month
- Unique visitors2.7K
per month
- Global rank#2,602,557
among all websites
- Category rank#3,566
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit3.8
- Average visit1 min 04 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Kohjin Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
saibou.jp | saibou.jp | 100% | – | #1,400,217 | – |
bmbio.com | bmbio.com | 87% | – | #647,837 | – |
bmsci.com | bmsci.com | 84% | – | #1,020,587 | – |
zenogenpharma.com | zenogenpharma.com | 83% | – | #8,366,573 | – |
| crodapharma.com | 82% | – | #1,182,931 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Kohjin Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Kohjin Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kohjin Bio
Complete news archive for Kohjin Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kohjin Bio
Kohjin Bio was founded in 1981.
Kohjin Bio is headquartered in Sakado, Japan. It is registered at Sakado, Saitama, Japan.
Takato Nakamura is the current CEO of Kohjin Bio.
Kohjin Bio has 167 employees.
Annual revenue of Kohjin Bio is $30.97M as on Mar 31, 2026.
Kohjin Bio was founded in 1981 in Sakado, Japan, as a provider of tissue culture media. Focus is placed on developing serum-free media for research applications in regenerative medicine and immunotherapy. Operations center on the production and supply of these specialized media to support scientific investigations in the biotechnology sector. The companys activities are based in Japan, serving global research needs.
Kohjin Bio's top competitors include Multus, Onkologic and Cellular Engineering Technologies.
Yes, Kohjin Bio is publicly traded on TSE under the ticker symbol 177A.